More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
When it comes to assessing patients with suspected pulmonary embolism, contrast-enhanced CT pulmonary angiography has no diagnostic edge over a certain free-breathing, unenhanced MRI perfusion protocol.
New research suggests that the tissue environment where microcalcifications of the breast are formed could hold clues into how breast cancer progresses.
Given the less invasive nature of focused ultrasound procedures, researchers suggest that it could open the door for disease management options catered to a wider variety of patients.
Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.
Many radiation oncologists are not formerly trained in imaging interpretation, and radiologists’ collaborative participation in care planning can help to catch errors, experts wrote recently.
While the studies on these systems have proven them to be effective in diagnosing and treating COVID in specific cohorts, the varying settings in which they were used can make it difficult to derive definitive conclusions on their efficacy.
